CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 250 of 275 entries

View as:

Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients

Phase: N/A Priority: Normal

NCT ID: NCT01201343 Org: User:

Start: 01/31/05 End: 07/31/10 Due: 07/31/11

Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Phase: N/A Priority: Normal

NCT ID: NCT00971932 Org: User:

Start: 07/31/09 End: - Due: -

Japanese Phase 1 Trial of Sym004 in Solid Tumors

Phase: N/A Priority: Normal

NCT ID: NCT01955473 Org: User:

Start: 10/31/13 End: 10/31/15 Due: 10/31/16

AS703569 and Gemcitabine Combination in Advanced Malignancies

Phase: N/A Priority: Normal

NCT ID: NCT01097512 Org: User:

Start: 06/30/07 End: 02/28/11 Due: 02/28/12

Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib

Phase: N/A Priority: Normal

NCT ID: NCT03629223 Org: User:

Start: 08/23/18 End: 01/25/19 Due: 01/25/20

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in South Korea

Phase: N/A Priority: Normal

NCT ID: NCT01259778 Org: User:

Start: 02/28/11 End: 12/31/15 Due: 12/31/16

A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies

Phase: N/A Priority: Normal

NCT ID: NCT00249808 Org: User:

Start: 12/13/04 End: 01/25/07 Due: 01/25/08

A Phase 1 TH-302 Mass Balance Trial

Phase: N/A Priority: Normal

NCT ID: NCT02076230 Org: User:

Start: 02/28/14 End: 03/31/16 Due: 03/31/17

c-Met Second-Line Hepatocellular Carcinoma

Phase: N/A Priority: Normal

NCT ID: NCT02115373 Org: User:

Start: 05/18/14 End: 02/14/18 Due: 02/14/19

Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control

Phase: N/A Priority: Normal

NCT ID: NCT01066039 Org: User:

Start: 04/30/10 End: 04/30/13 Due: 04/30/14

Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)

Phase: N/A Priority: Normal

NCT ID: NCT01080053 Org: User:

Start: 11/30/08 End: 05/31/13 Due: 05/31/14

Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease

Phase: N/A Priority: Normal

NCT ID: NCT00157196 Org: User:

Start: 04/30/05 End: 04/30/12 Due: 04/30/13

Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants

Phase: N/A Priority: Normal

NCT ID: NCT03026088 Org: User:

Start: 03/21/17 End: 12/26/18 Due: 12/26/19

Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants

Phase: N/A Priority: Normal

NCT ID: NCT03467945 Org: User:

Start: 02/16/18 End: 04/29/18 Due: 04/29/19

Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension

Phase: N/A Priority: Normal

NCT ID: NCT01977794 Org: User:

Start: 03/31/14 End: 03/31/15 Due: 03/31/16

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

Phase: N/A Priority: Normal

NCT ID: NCT03492437 Org: User:

Start: 05/17/18 End: 08/27/18 Due: 08/27/19

An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period

Phase: N/A Priority: Normal

NCT ID: NCT01112657 Org: User:

Start: 11/30/08 End: 10/31/14 Due: 10/31/15

PERgoveriS In Stratified Treatment for Assisted Reproductive Technique

Phase: N/A Priority: Normal

NCT ID: NCT01297465 Org: User:

Start: 05/31/11 End: 10/31/12 Due: 10/31/13

Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis

Phase: N/A Priority: Normal

NCT ID: NCT01080573 Org: User:

Start: 01/31/07 End: 04/30/11 Due: 04/30/12

TICON-Day 3, Time Lapse Versus Conventional Method in Day 3 Embryo Culture and Assessment

Phase: N/A Priority: Normal

NCT ID: NCT03164551 Org: User:

Start: 04/16/18 End: 11/20/19 Due: 11/20/20

A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α

Phase: N/A Priority: Normal

NCT ID: NCT01111084 Org: User:

Start: 03/31/04 End: 06/30/05 Due: 06/30/06

A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood

Phase: N/A Priority: Normal

NCT ID: NCT01157793 Org: User:

Start: 09/30/03 End: 02/28/05 Due: 02/28/06

Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

Phase: N/A Priority: Normal

NCT ID: NCT03717155 Org: User:

Start: 10/30/18 End: 05/27/21 Due: 05/27/22

Metabolic Endocrinology and Growth Hormone in Adults

Phase: N/A Priority: Normal

NCT ID: NCT01080755 Org: User:

Start: 12/31/03 End: 09/30/12 Due: 09/30/13

Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects

Phase: N/A Priority: Normal

NCT ID: NCT01012258 Org: User:

Start: 02/28/09 End: 05/31/14 Due: 05/31/15

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients	NCT01201343	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2005-01-31	2010-07-31	2011-07-31	-	-	2025-07-14
Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	NCT00971932	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-07-31	-	-	-	-	2025-07-14
Japanese Phase 1 Trial of Sym004 in Solid Tumors	NCT01955473	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2013-10-31	2015-10-31	2016-10-31	-	-	2025-07-14
AS703569 and Gemcitabine Combination in Advanced Malignancies	NCT01097512	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2007-06-30	2011-02-28	2012-02-28	-	-	2025-07-14
Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib	NCT03629223	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2018-08-23	2019-01-25	2020-01-25	-	-	2025-07-14
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in South Korea	NCT01259778	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2011-02-28	2015-12-31	2016-12-31	-	-	2025-07-14
A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies	NCT00249808	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2004-12-13	2007-01-25	2008-01-25	-	-	2025-07-14
A Phase 1 TH-302 Mass Balance Trial	NCT02076230	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2014-02-28	2016-03-31	2017-03-31	-	-	2025-07-14
c-Met Second-Line Hepatocellular Carcinoma	NCT02115373	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2014-05-18	2018-02-14	2019-02-14	-	-	2025-07-14
Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control	NCT01066039	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2010-04-30	2013-04-30	2014-04-30	-	-	2025-07-14
Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)	NCT01080053	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2008-11-30	2013-05-31	2014-05-31	-	-	2025-07-14
Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease	NCT00157196	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2005-04-30	2012-04-30	2013-04-30	-	-	2025-07-14
Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants	NCT03026088	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2017-03-21	2018-12-26	2019-12-26	-	-	2025-07-14
Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants	NCT03467945	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2018-02-16	2018-04-29	2019-04-29	-	-	2025-07-14
Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension	NCT01977794	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2014-03-31	2015-03-31	2016-03-31	-	-	2025-07-14
Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate	NCT03492437	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2018-05-17	2018-08-27	2019-08-27	-	-	2025-07-14
An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period	NCT01112657	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2008-11-30	2014-10-31	2015-10-31	-	-	2025-07-14
PERgoveriS In Stratified Treatment for Assisted Reproductive Technique	NCT01297465	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2011-05-31	2012-10-31	2013-10-31	-	-	2025-07-14
Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis	NCT01080573	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2007-01-31	2011-04-30	2012-04-30	-	-	2025-07-14
TICON-Day 3, Time Lapse Versus Conventional Method in Day 3 Embryo Culture and Assessment	NCT03164551	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2018-04-16	2019-11-20	2020-11-20	-	-	2025-07-14
A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α	NCT01111084	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2004-03-31	2005-06-30	2006-06-30	-	-	2025-07-14
A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood	NCT01157793	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2003-09-30	2005-02-28	2006-02-28	-	-	2025-07-14
Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC	NCT03717155	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2018-10-30	2021-05-27	2022-05-27	-	-	2025-07-14
Metabolic Endocrinology and Growth Hormone in Adults	NCT01080755	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2003-12-31	2012-09-30	2013-09-30	-	-	2025-07-14
Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects	NCT01012258	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-02-28	2014-05-31	2015-05-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance